

Self-medication with NSAIDs and purchase of branded and over-the-counter medicines: Analysis of a national survey in Peru

Journal of Public Health Research
2025, Vol. 14(1), 1–11
© The Author(s) 2025
DOI: 10.1177/22799036251319154
journals.sagepub.com/home/phj



Jerry K Benites-Meza^{1,2}, Liseth Pinedo-Castillo³, Miguel Cabanillas-Lazo⁴,
María A Boyd-Gamarra^{5,6}, Percy Herrera-Añazco⁷, Benoit Mougenot^{8,9},
and Vicente A Benites-Zapata¹⁰

Abstract

Background: This study aimed to determine the association between self-medications with nonsteroidal anti-inflammatory drugs (NSAIDs) and the purchase of branded and over-the-counter medications in Peru.

Design and methods: This secondary analysis used a representative survey of Peru from 2014 to 2016. The exposure variable was self-medication with NSAIDs, defined as “the purchase of NSAIDs for oneself without a prescription.” The outcome was the purchase of branded and over-the-counter medications. Crude prevalence ratios (cPR) and adjusted prevalence ratios (aPR) with their respective 95% confidence intervals (95% CI) were calculated.

Results: Of the total of 2158 participants, 52.80% were women with an average age of 40.24 years. The prevalence of self-medication with NSAIDs was 68.21%, whereas the rates of purchasing branded and over-the-counter medications were 63.78% and 13.16%, respectively. The adjusted Poisson regression analysis showed an association between self-medication with NSAIDs and the purchase of branded (aPR = 1.18; 95% CI: 1.12–1.25; $p < 0.001$) and over-the-counter (aPR = 2.38; 95% CI: 1.95–2.90; $p < 0.001$) medications.

Conclusions: Approximately 7/10 users who self-medicate with NSAIDs chose branded medications, whereas nearly 1/5 opt for over-the-counter medications. Self-medication with NSAIDs was associated with a higher likelihood of purchasing branded and over-the-counter medications.

Keywords

Self-medication, NSAIDs, drugs, generic drugs, Peru

Date received: 1 May 2024; accepted: 23 January 2025

¹Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Trujillo, Trujillo, Peru

²Grupo Peruano de Investigación Epidemiológica, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru

³Universidad Señor de Sipán, Chiclayo, Peru

⁴Universidad de Huánuco, Huánuco, Peru

⁵Escuela Profesional de Medicina Humana de la Universidad Señor de Sipán, Chiclayo, Peru

⁶Asociación Científica de Estudiantes de Medicina de la Universidad Señor de Sipán, Chiclayo, Peru

⁷Universidad Privada del Norte, Trujillo, Peru

⁸Facultad de Ciencias Empresariales, Universidad San Ignacio de Loyola, Lima, Peru

⁹Centro de Excelencia en Investigaciones Económicas y Sociales en Salud, Universidad San Ignacio de Loyola, Lima, Peru

¹⁰Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru

Jerry K Benites-Meza is also affiliated with NOVA Evidence Research Group, Trujillo, Peru.

Liseth Pinedo-Castillo is also affiliated with Grupo Peruano de Investigación Epidemiológica, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru.

Corresponding author:

Vicente A. Benites-Zapata, Vicerectorado de Investigación, Universidad San Ignacio de Loyola, Campus 2, Avenida La Fontana 750, La Molina, Lima 15032, Peru.

Email: vbenites@usil.edu.pe



Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most used medications worldwide and in Peru given their easy availability without the need for medical prescription^{1,2} and well-known analgesic, anti-inflammatory, and antipyretic effects.^{3–5} This trend significantly affects the pharmaceutical market and the monitoring of patients' consumption habits.⁶ In addition to their benefits, they have harmful adverse effects when used inappropriately.⁷ Despite this, the prevalence of polypharmacy and inappropriate self-medication with NSAIDs remains high.^{1,8}

Several factors affect the choice of medicines, and advertising by pharmaceutical industries is a significant driver⁹ as they heavily invest in marketing to promote product sales.¹⁰ In addition to fewer adverse effects, this choice may be linked to the perception of safety, trust, quality, and effectiveness associated with the brand.¹¹

Another factor to consider is whether the chosen medication is generic or branded, with cost considerations playing a key role. In the United States, dispensing branded medications incurred an incremental annual cost of \$270 million for patients compared to their generic equivalents.¹² This cost could increase in the coming years, as prices for the most commonly used branded medications have doubled in the last 5 years.¹³ This could affect therapy adherence and interruption caused by increased out-of-pocket spending,¹⁴ unlike the use of generic medications, which has been associated with better adherence probably owing to their costs.¹⁵ In developed countries, prescription medications are replaced by over-the-counter medications, potentially affecting patients' out-of-pocket expenses. However, there is concern about their use given the higher frequency of adverse effects and less followup,^{16,17} particularly in self-medicating individuals.¹⁸ These adverse effects include risk of gastric and small intestinal mucosal lesions, cardiovascular disease, kidney injury, hepatotoxicity, intracerebral hemorrhage, or respiratory tract inflammation and infection.³ However, NSAIDs may be relatively safe when prescribed at a low dose and shortest time (≤ 10 days). Exceptions would be for patients at risk of developing NSAID-exacerbated respiratory diseases and patients with prior myocardial infarction who are receiving antithrombotic therapy, asthma, and history of renal disease.¹⁹

Several studies have shown the characteristics of NSAID use among the general and vulnerable populations, as well as self-medication.^{20–24} To the best of our knowledge, no study has evaluated the choice of branded or over-the-counter medications among patients who self-medicate with NSAIDs. Peru, similar to other South American countries, has a fragmented health system, and restrictions on access to health services.²⁵ This forces users to seek other alternatives to solve their ailments, such as home remedies or self-medications.²⁶ Therefore, older

adults prefer branded medications instead of over-the-counter ones,²⁷ which could be also observed in the case of NSAIDs. Therefore, this study aimed to determine the association between self-medication with NSAIDs and the purchase of branded and over-the-counter medications among Peruvian users.

Methods

Study design

This is a cross-sectional analytical observational study through the secondary analysis of the fourth questionnaire of the National Health User Satisfaction Survey 2014–2016 (ENSUSALUD) of the National Institute of Statistics and Informatics of Peru and the National Superintendency of Health of Peru (SUSALUD). ENSUSALUD was a nationally representative survey that aimed to obtain information on the functioning of Health Service Providing Institutions (IPRESS) based on the information provided by users and providers of said services.²⁸

Population, sample, and sampling

The study population consisted of people aged ≥ 15 years who purchased medications for themselves, their partner, or their child at a pharmacy or drug store near IPRESSs nationwide.²⁸ Two-stage probabilistic stratified sampling was conducted at 181 IPRESSs.²⁸

The primary sampling units were the IPRESSs of the Ministry of Health and regional governments (MINSA-GR), Social Health Insurance in Peru (EsSalud), Health Services of the Armed and Police Forces (health services), and private sector clinics (CSP), which were randomly selected. The secondary unit was the users of pharmacies and drug stores who were chosen nonprobabilistically by convenience.²⁸ In total, 25 strata correspond to the 25 political regions of Peru based on which the expansion factors were estimated. Inference was limited to care in the outpatient medical consultations of IPRESSs within the country.

Eligibility criteria. All participants aged > 18 years who had purchased at least one NSAID for themselves at a pharmacy or drug store close to a healthcare facility were included. Participants who had missing data on some of the variables of interest were excluded (Figure 1).

Variables. Two outcomes were considered: the use of branded NSAIDs, defined as “the purchase of at least one branded NSAID,” and the use of over-the-counter medications, also defined as “the purchase of at least one over-the-counter medication.” Both variables were constructed from the registry of medicines purchased by users and were classified using the Pharmaceutical Products Health Registry of Peru (<https://www.digemid.minsa.gob.pe/>)




Figure 1. Flowchart of the selection of participants included in the analysis, ENSUSALUD 2014–2016.

rsProductosFarmaceuticos/). For both variables, duplicate coding was corrected by a third author as performed previously in other studies.^{27,29,30} In Peru, all medications are authorized by the Ministry of Health. According to their name, they are marketed as branded or generic medications: branded drugs use a name assigned by a pharmaceutical company, whereas generics are named by the drug's active ingredient. Furthermore, the condition of sale, such as controlled or over-the-counter sale, refers to the need for a medical prescription or lack thereof. According to Peruvian law, doctors, dentists, and obstetricians are healthcare professional qualified to issue a medical prescription.

The main exposure variable was the practice of self-medication, which considered participants who purchased medications for themselves without a prescription and those who did not show the prescription at the time of the survey, as described in previous studies.^{27,29}

According to the literature, the following as confounding variables were considered: sex (female or male), age (18–39, 40–59, or ≥ 60 years), educational level (higher

university, higher nonuniversity, high school, primary, or lower), language (Spanish or Quechua/others), health insurance (yes or no), type of institution (drug store or pharmacy), and geographic region of residence (metropolitan Lima, other regions of the coast, mountains, or jungle).

Ethical aspects. ENSUSALUD is a free, open-access database that belongs to the SUSALUD service (<http://portal.susalud.gob.pe/blog/category/base-de-datos/>). All potential participants provided verbal consent to participate in the survey. No identifying information was collected from participants to ensure the confidentiality of their responses. Furthermore, this study involved a secondary analysis of free data without personal identifiers that comply with international regulations; thus, it is exempt from ethics committee review.

Statistical analysis. The ENSUSALUD databases corresponding to the period from 2014 to 2016 were downloaded in SPSS format and then exported and analyzed

using STATA v16.0 software (TX, StataCorp LP). All sampling patterns were analyzed according to stratum and weighting factor, considering the complex sampling design of ENSUSALUD and using the *svy* command.

In the descriptive analysis, categorical variables are expressed as frequencies and percentages with their respective 95% confidence intervals (95% CIs). Numerical variables are presented as averages with their 95% CIs. The chi-square test with Rao Scott correction for complex sampling was used to determine significant differences between the independent variables according to the proposed outcomes.

Generalized linear models of the Poisson family were made to determine the association between self-medication with NSAIDs and the purchase of branded and over-the-counter medications, and prevalence ratios with their respective 95% CIs were reported. An adjusted analysis was performed considering the confounders and based on an epidemiological criterion. To evaluate collinearity, the variance inflation factors were determined by setting an accepted value at <5 . A *p*-value of <0.05 was set as significant.

Results

This study analyzed a sample of 2158 adults who purchased NSAIDs for themselves (Figure 1). Of these, 52.80% were women, the mean age was 40.24 (95% CI, 39.61–40.87) years, 39.42% lived in the jungle, and 37.36% had secondary education. Furthermore, 62.03% had health insurance, and 85.00% bought their medications at pharmacies. The frequencies of self-medication with NSAIDs, purchase of branded medications, and purchase of over-the-counter medications were 68.21%, 63.78%, and 13.16%, respectively (Table 1).

Among patients who self-medicated with NSAIDs, a higher proportion of participants self-medicated with branded (66.20%) and over-the-counter medications (16.23%) and among participants aged 18–39 years (60.36%). Conversely, a lower proportion of those had health insurance (58.33%) and purchased their medications at a pharmacy (84.69%). Furthermore, the highest and lowest proportions of participants who self-medicated resided in the jungle (42.8%) and mountains (13.26%), respectively (Table 2).

The most frequently acquired NSAIDs were oxicams (66.28%), propionics (44.92%), and acetics (41.42%; Table 3). According to NSAID types, the proportions of self-medicating users of propionics (49.90% vs 34.25%; $p < 0.001$) and salicylates (8.64% vs 5.10%; $p < 0.001$) were higher. In contrast, the proportions of self-medicating users of acetics (38.54% vs 47.61%; $p < 0.001$), COX-2 (6.90% vs 19.24%; $p < 0.001$), oxicams (4.81% vs 10.52%; $p < 0.001$), and pyrazolones (1.54% vs 2.11%; $p = 0.002$) were lower (Table 2). Moreover, salicylates (10.28% vs

Table 1. General characteristics of users of drugstores and pharmacies, ENSUSALUD 2014–2016 ($n = 2158$; $N = 634,464$).

Characteristics	Absolute frequency	Weighted proportion*	
	<i>n</i>	%	95% CI
Self-medication			
No	649	31.79	29.83–33.81
Yes	1509	68.21	66.19–70.17
Brand-name drugs			
No	802	36.22	34.45–38.02
Yes	1356	63.78	61.98–65.55
Over-the-counter drugs			
No	1872	86.84	85.86–87.76
Yes	286	13.16	12.24–14.14
Sex			
Women	1154	52.80	50.66–54.94
Men	1004	47.20	45.06–49.34
Age (years)			
Mean (95% CI)	40.24		39.61–40.87
18–39	1186	54.63	52.41–56.83
40–59	689	31.88	29.96–33.86
60 and older	283	13.49	12.15–14.95
Education level			
University education	582	27.94	26.10–29.85
Non-university higher education	438	19.50	18.13–20.94
High school	785	37.36	35.52–39.23
Complete elementary education or below	353	15.20	14.11–16.39
Health insurance			
No	754	37.97	36.40–39.57
Yes	1404	62.03	60.43–63.60
Language			
Spanish	2097	97.54	97.15–97.88
Quechua/Others	61	2.46	2.12–2.85
Type of institution			
Drugstore	326	15.00	13.83–16.26
Pharmacy	1832	85.00	83.74–86.17
Geographic region of residency			
Metropolitan Lima	240	25.36	22.01–29.03
Other areas of Coast region	621	22.53	18.46–27.20
Highlands	376	12.69	11.53–13.94
Jungle	921	39.42	36.63–42.29

*Weights and the design effect of the complex survey sampling were included.

2.65%; $p < 0.001$), acetics (43.79% vs 37.26%; $p = 0.001$), and pyrazolones (1.83% vs 1.04%; $p = 0.039$) were more likely to be purchased as branded medications compared with propionics (39.08% vs 55.21%; $p < 0.001$; Table 3).

Furthermore, salicylates (48.41% vs 1.32%; $p < 0.001$) and propionics (52.53% vs 43.77%; $p = 0.001$) were more likely to be purchased as over-the-counter medications

Table 2. General characteristics of users of drugstores and pharmacies according to self-medication.

Characteristics	Self-medication <i>n</i> = 1509		No self-medication <i>n</i> = 649		<i>p</i> -value*
	<i>n</i>	%	<i>n</i>	%	
Brand-name drugs					<0.001
No	518	33.80	284	41.40	
Yes	991	66.20	365	58.60	
Over-the-counter drugs					<0.001
No	1261	83.77	611	93.41	
Yes	248	16.23	38	6.59	
Sex					0.624
Women	795	52.52	359	53.40	
Men	714	47.48	290	46.60	
Age (years)					<0.001
18–39	891	60.36	295	42.34	
40–59	447	28.30	242	39.57	
60 and older	171	11.34	112	18.09	
Education level					<0.001
University education	440	30.70	142	22.02	
Non-university higher education	300	18.76	138	21.07	
High school	549	37.33	236	37.41	
Complete elementary education or below	220	13.21	133	19.50	
Health insurance					<0.001
No	573	41.67	181	30.03	
Yes	936	58.33	468	69.97	
Language					0.122
Spanish	1467	97.42	630	97.80	
Quechua/Others	42	2.58	19	2.20	
Type of institution					<0.001
Drugstore	225	15.31	101	14.36	
Pharmacy	1284	84.69	548	85.64	
Geographic region of residency					<0.001
Metropolitan Lima	150	23.24	90	29.92	
Other areas of Coast region	405	20.70	216	26.45	
Highlands	269	13.26	107	11.47	
Jungle	685	42.80	236	32.16	
NSAIDs family					<0.001
Salicylates					
No	1381	91.36	621	94.90	
Yes	128	8.64	28	5.10	
Propionics					<0.001
No	732	50.10	406	65.75	
Yes	777	49.90	243	34.25	
Acetics					<0.001
No	934	61.46	336	52.39	
Yes	575	38.54	313	47.61	
Oxicams					<0.001
No	1447	95.19	592	89.48	
Yes	62	4.81	57	10.52	
Pyrazolonics					0.002
No	1493	98.46	637	97.89	
Yes	16	1.54	12	2.11	
COX-2					<0.001
No	1412	93.10	547	80.76	
Yes	97	6.90	102	19.24	

Weights and the design effect of the complex survey sampling were included.

*Refers to the statistical significance obtained from the comparison of the proportions between the categories of the variables considering the complex sampling of the survey.

Table 3. Types of medicine purchased by users of drugstores and pharmacies according to the use of brand-name and OTC drugs.

Type of medicine purchased by participants	All <i>n</i> = 2158		Brand-name drugs <i>n</i> = 1356		Generic drugs <i>n</i> = 802		<i>p</i> -value*	Over-the-counter drugs <i>n</i> = 286		Controlled sale drugs <i>n</i> = 1872		<i>p</i> -value*
	<i>N</i>	%	<i>N</i>	%	<i>N</i>	%		<i>N</i>	%	<i>N</i>	%	
Salicylates							<0.001					<0.001
No	2002	92.49	1220	89.72	782	97.35		154	51.59	1848	98.68	
Yes	156	7.51	136	10.28	20	2.65		132	48.41	24	1.32	
Propionics							<0.001					0.001
No	1138	55.08	811	60.92	327	44.79		129	47.47	1009	56.23	
Yes	1020	44.92	545	39.08	475	55.21		157	52.53	863	43.77	
Acetics							0.001					<0.001
No	1270	58.58	746	56.21	524	62.74		278	96.62	992	52.81	
Yes	888	41.42	610	43.79	278	37.26		8	3.38	880	47.19	
Oxicams							0.269					<0.001
No	2039	93.37	1285	93.79	754	92.64		286	100.00	1753	92.37	
Yes	119	66.28	71	6.21	48	7.36		0	0.00	119	7.63	
Pyrazolones							0.039					<0.001
No	2130	98.46	1336	98.17	794	98.96		285	99.82	1845	98.25	
Yes	28	1.54	20	1.83	8	1.04		1	0.18	27	1.75	
COX-2							0.408					<0.001
No	1959	89.18	1227	88.83	732	89.79		286	100.00	1673	87.54	
Yes	199	10.82	129	11.17	70	10.21		0	0.00	199	12.46	

Weights and the design effect of the complex survey sampling were included.

*Refers to the statistical significance obtained from the comparison of the proportions between the categories of the variables considering the complex sampling of the survey.

compared with controlled sales. Conversely, acetics (3.38% vs 47.19%; $p < 0.001$), oxicams (0.00% vs 7.63%; $p < 0.001$), pyrazolones (0.18% vs 1.75%; $p < 0.001$), and COX-2 (0.00% vs 12.46%; $p < 0.001$) were less likely to be purchased as branded drugs (Table 3).

Branded NSAIDs were more frequently purchased by self-medicating participants (66.20%), those aged 40–59 years (66.58%), and those who resided in other coastal areas (74.18%) than by those who lived in the jungle (55.91%; $p < 0.001$). The purchase was lower among those who spoke Quechua or other languages than those who spoke Spanish (51.46% vs 64.09%; $p < 0.001$; Table 4). As for the over-the-counter NSAIDs, the purchase rate was higher among those who self-medicated (16.23%), those aged 18–39 years (15.00%), and those with a university education (16.41%). However, men had a lower purchase rate than women (9.94% vs 16.05%; $p < 0.001$; Table 4).

A significant association was found between self-medication with NSAIDs and the purchase of branded medications in the crude (crude prevalence ratios [cPR]: 1.13; 95% CI: 1.07–1.19; $p < 0.001$) and adjusted (aPR: 1.18; 95% CI: 1.12–1.25; $p < 0.001$) analyses. A greater probability of purchasing over-the-counter medications was found among those who self-medicated in the crude

(cPR: 2.46; 95% CI: 2.01–3.01; $p < 0.001$) and adjusted (aPR: 2.38; 95% CI: 1.95–2.90; $p < 0.001$) analyses (Table 5).

Discussion

This study primarily reveals that 7 out of 10 participants self-medicated with NSAIDs, predominantly opting for propionics and salicylates. It was more common for them to self-medicate with branded NSAIDs; in those cases, acetics, salicylates, and pyrazolones were more common. Finally, an association was found between self-medication with NSAIDs and the purchase of branded and over-the-counter medications.

The frequency of self-medication with NSAIDs was similar to that reported in most investigations in other countries. In a narrative review that conducted a systematic search in various databases and found 24 articles related to self-medication with NSAIDs, the prevalence of self-medication was >50% in 70.3% of articles, whereas the prevalence was <50% in 25% of articles.³¹ The discrepancies were attributed to the differences in the sociodemographic characteristics of the samples, study methods, populations, and data collection instruments.³¹

Table 4. General characteristics of users of drugstores and pharmacies according to the use of brand-name and OTC drugs.

Characteristics	Brand-name drugs n = 1356			Generic drugs n = 802			p-value*	Over-the-counter drugs n = 286			Controlled sale drugs n = 1872			p-value*
	n	%	95% CI	n	%	95% CI		n	%	95% CI	n	%	95% CI	
Self-medication							<0.001							<0.001
No	365	58.60	55.59–61.55	284	41.40	38.45–44.41		38	6.59	5.48–7.90	611	93.41	92.10–94.52	
Yes	991	66.20	64.19–68.14	518	33.80	31.86–35.81		248	16.23	14.98–17.55	1261	83.77	82.45–85.02	
Sex							0.469							<0.001
Women	719	63.23	60.99–65.41	435	36.77	34.59–39.01		185	16.05	14.46–17.77	969	83.95	82.23–85.54	
Men	637	64.40	61.77–66.94	367	35.60	33.06–38.23		101	9.94	8.98–10.98	903	90.06	89.02–91.02	
Age (years)							0.024							0.002
18–39	721	61.86	59.19–64.46	465	38.14	35.54–40.81		181	15.00	13.50–16.63	1005	85.00	83.37–86.50	
40–59	452	66.58	64.13–68.95	237	33.42	31.05–35.87		68	10.13	8.34–12.26	621	89.87	87.75–91.66	
60 and older	183	64.94	60.81–68.86	100	35.06	31.14–39.19		37	12.89	10.67–15.48	246	87.11	84.52–89.33	
Education level							0.889							0.002
University education	361	63.04	59.61–66.35	221	36.96	33.65–40.39		101	16.41	14.31–18.76	481	83.59	81.24–85.69	
Non-university higher education	269	63.43	59.91–66.8	169	36.57	33.20–40.08		53	11.61	9.67–13.88	385	88.39	86.12–90.33	
High school	497	64.49	61.61–67.27	288	35.51	32.73–38.39		98	12.72	11.33–14.26	687	87.28	85.74–88.67	
Complete elementary education or below	229	63.85	60.41–67.15	124	36.15	32.85–39.59		34	10.26	8.69–12.08	319	89.74	87.92–91.31	
Health insurance							0.126							0.844
No	492	65.46	62.77–68.06	262	34.54	31.94–37.23		113	13.32	11.63–15.21	641	86.68	84.79–88.37	
Yes	864	62.75	60.38–65.06	540	37.25	34.94–39.62		173	13.07	11.71–14.55	1231	86.93	85.45–88.29	
Language							<0.001							0.638
Spanish	1319	64.09	62.26–65.88	778	35.91	34.12–37.74		276	13.15	12.22–14.14	1821	86.85	85.86–87.78	
Quechua/Others	37	51.46	44.71–58.17	24	48.54	41.83–55.29		10	13.64	11.67–15.88	51	86.36	84.12–88.33	
Type of institution							0.572							0.409
Drugstore	203	62.80	59.83–65.67	123	37.20	34.33–40.17		40	12.11	9.87–14.77	286	87.89	85.23–90.13	
Pharmacy	1153	63.95	61.76–66.09	679	36.05	33.91–38.24		246	13.35	12.26–14.51	1586	86.65	85.49–87.74	
Geographic region of residency							<0.001							0.351
Metropolitan Lima	164	68.33	62.61–73.55	76	31.67	26.45–37.39		27	11.25	8.66–14.49	213	88.75	85.51–91.34	
Other areas of Coast region	434	74.18	71.16–76.98	187	25.82	23.02–28.84		77	14.39	11.90–17.30	544	85.61	82.70–88.10	
Highlands	227	60.68	56.59–64.62	149	39.32	35.38–43.41		54	13.48	11.19–16.27	322	86.52	83.73–88.90	
Jungle	531	55.91	53.69–58.11	390	44.09	41.89–46.31		128	13.59	11.99–15.36	793	86.41	84.64–88.01	

Weights and the design effect of the complex survey sampling were included.

*Refers to the statistical significance obtained from the comparison of the proportions between the categories of the variables considering the complex sampling of the survey.

Table 5. Association between self-medication with NSAIDs and the use of brand-name and OTC drugs in users of drugstores and pharmacies.

Variable	Exposure	Crude model ^a			Adjusted model ^{a,b}		
		PR	95% CI	p-value	PR	95% CI	p-value
Brand-name drugs							
Self-medication	No	Ref.	—	—	Ref.	—	—
	Yes	1.13	1.07–1.19	<0.001	1.18	1.12–1.25	<0.001
Over-the-counter drugs							
Self-medication	No	Ref.	—	—	Ref.	—	—
	Yes	2.46	2.01–3.01	<0.001	2.38	1.95–2.90	<0.001

PR: Prevalence ratio; **95% CI:** 95% Confidence intervals.

^aA generalized linear model of the Poisson family was carried out with link log considering the effect of the design and the weights of the complex sampling of the survey.

^bAdjusted for age, sex, education level, language, health insurance, geographic region of residence, and type of institution.

Regarding the NSAID types, the review proposed that the most purchased drugs for self-medication were ibuprofen, diclofenac (25% of articles), and aspirin (16.65% of articles).³¹ This is consistent with our results, where propionics and salicylates were the most purchased in both generic and branded medications. Although our results do not explain this choice, it may be related to the reasons behind purchasing these medications. In 41.67% of the articles, NSAIDs were used to relieve headaches; in 20.83%, they were used for menstrual cramps; and in 16.67%, they were used to relieve fever and toothache.³¹ Briefly, NSAIDs are used to manage health issues that individuals may not consider requiring medical consultation, often due to the “habitual” nature of self-medication. This tendency could also explain the preference for over-the-counter NSAIDs as observed in this study. Although some NSAIDs in Peru require a medical prescription, the supervision is lax, and practically all are available over-the-counter, where the purchasing decision may be influenced by advertising. A study conducted in metropolitan Lima revealed that 70% of their respondents indicated that advertising influences their decision to purchase NSAIDs at the pharmacy.³²

Furthermore, our results show sex differences in self-medication with over-the-counter NSAIDs, with women purchasing them the most. This is inconsistent with the results of another study performed in our country, which revealed that men were generally associated with self-medication.² A possible explanation could include the most frequent reasons for NSAID use that are more common among women, such as menstrual cramps and headache.³¹ In addition, the age-adjusted incidence of pain of any type is higher among women.³³ Similarly, patients with higher education levels tended to use over-the-counter medications, which, although other studies have shown similar results,³⁴ is not a universal finding.³⁵ Although we did not examine the reasons for these findings, other authors propose that individuals with higher educational levels tend to have better health knowledge about diseases and medications, higher self-confidence in making appropriate decisions about self-medication, and less faith in the quality of formal health services.³⁴

The improvement of universal insurance coverage in Peru has increased the likelihood of receiving care at a health facility.³⁶ Although out-of-pocket spending remains a public health problem,³⁷ this improvement enhanced access to NSAIDs, as indicated by the results of this study. However, these improvements are not homogeneous, with some gaps still unresolved in some regions such as the jungle,³⁸ with the highest proportion of people self-medicating with NSAIDs. Interestingly, the lowest self-medication rate was observed in mountainous regions, even if both regions are generally associated with self-medication.² The unique use of traditional medicines for conditions typically treated with NSAIDs could influence these

findings,³⁹ as well as whether self-medication is self-perceived as being responsible or not.⁴⁰

This study showed that 7 out of 10 people who self-medicate with NSAIDs prefer branded medications. Although we did not explore the reasons behind these preferences, they may be attributed to the demand for branded medications as a result of the limited availability of generic medications at healthcare facilities.⁴¹ Furthermore, the sales strategies of private pharmacies, which prioritize the marketing of branded products, along with the prevalent perception that generic medications are inferior to branded ones, may affect this choice.⁴² Moreover, there is distrust in the use of generic medications, mainly due to concerns regarding their therapeutic effect, potency, or adverse effect.⁴³ In Peru, they are perceived as less effective and more likely to have side effects, and branded medications are preferred even if they have the same price as the generic ones.¹¹ This preference for branded medications is often associated with lower levels of health literacy and education.⁴⁴ Conversely, the preference for generic medications is associated with the perception of a mild illness, self-initiated treatment, or individuals feeling adequately informed about these drugs.⁴⁵ As in self-medication in general, advertising can also influence their choice³² and is aimed at populations with more purchasing power. This could explain our finding that patients from the jungle or those speaking indigenous languages, which are traditionally vulnerable populations,⁴⁶ tend to purchase fewer branded NSAIDs.

The present results have implications for public health, highlighting the widespread and indiscriminate use of NSAIDs, which poses a significant challenge to healthcare systems worldwide. This indiscriminate use is associated with the risk of serious or life-threatening complications^{47–49}; thus, policies are needed to mitigate their overuse. Although self-medication is the problem, medical consultations offer an opportunity to educate patients about the adverse effects of NSAIDs⁵⁰ and inform them about reports from pharmacovigilance services regarding identified adverse effects.⁵¹ Furthermore, concerns are increasing about the purchase of commercial medications at the expense of generic ones, requiring a policy aimed at facilitating their purchase. The “Reference Prices” methodology is used in European countries, where the government’s health system calculates and finances each medicine according to this criterion. If a medical prescription includes a drug with higher price, the pharmacist is obligated to replace it with a generic one.⁵² However, in countries such as Peru, where laboratories encourage self-medication and invest high amounts in advertising,¹⁰ control and regulations have begun in the last decade. Therefore, the list of essential generic drugs was recently modified, and they must be available in pharmacies, drug stores, and private services.⁵³

Limitations

This study has some limitations. First, given the secondary cross-sectional design, it is not possible to establish a causal relationship between self-medication with NSAIDs and the proposed outcomes. However, an epidemiological approach was followed to adjust for confounders. Second, many variables were obtained from participants' self-report. However, the questions were asked at pharmacies and drugstores after participants had purchased their medications, which could reduce selection bias. Third, unmeasured variables, comorbidities such as chronic pain, which forced continuous use of NSAIDs, or socioeconomic status and limited the use of health insurance and forced self-medication, must be considered. Fourth, the results were influenced by manner by which the survey collected information on the two main variables. Despite these limitations, this study provides information representative of the Peruvian population.

Conclusions

This study revealed a widespread and indiscriminate use of NSAIDs in Peru; most of it was with the purchase of branded medications. Thus, patients must be educated about the adverse effects of NSAIDs and policies aimed at facilitating the purchase of generic drugs.

Significance for public health

This study aimed to determine the association between self-medication with nonsteroidal anti-inflammatory drugs (NSAIDs) and the purchase of branded and over-the-counter medicines in Peru to gain a deeper understanding of the factors that influence the treatment decisions of the Peruvian population. Data from 2158 participants were analyzed, the prevalence of self-medication with NSAIDs was 68.21%, and the rate of purchase of branded medicines was 63.78%. Prevalence data of self-medication are crucial for the design of public health interventions and policies that promote safe and effective use of medicines while addressing challenges related to accessibility, affordability, and confidence in generic products. By identifying gaps in health knowledge and practices, this study can help inform educational programs aimed at improving health literacy and promoting healthier behaviors in the Peruvian population.

Consent to participate

All potential participants provided verbal consent to participate in the survey








Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Jerry K Benites-Meza  <https://orcid.org/0000-0002-6085-7431>
 Liseth Pinedo-Castillo  <https://orcid.org/0000-0002-7018-4939>
 Miguel Cabanillas-Lazo  <https://orcid.org/0000-0002-9976-0530>
 Maria A Boyd-Gamarra  <https://orcid.org/0000-0001-6606-999X>
 Percy Herrera-Añazco  <https://orcid.org/0000-0003-0282-6634>
 Benoit Mougenot  <https://orcid.org/0000-0001-5956-7659>
 Vicente A Benites-Zapata  <https://orcid.org/0000-0002-9158-1108>

References

1. Hermoza-Moquillaza R, Loza-Munarriz C, Rodríguez-Hurtado D, et al. Automedicación en un distrito de Lima Metropolitana, Perú. *Rev Med Herediana* 2016; 27(1): 15.
2. Urrunaga-Pastor D, Benites-Zapata VA and Mezones-Holguín E. Factors associated with self-medication in users of drugstores and pharmacies in Peru: an analysis of the National Survey on User Satisfaction of Health Services, ENSUSALUD 2015. *F1000Res* 2020; 8: 23.
3. Bindu S, Mazumder S and Bandyopadhyay U. Nonsteroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. *Biochem Pharmacol* 2020; 180: 114147.
4. Abdu-Aguye SN, Shehu A and Ahmad UI. Management of musculoskeletal pain in retail drug outlets within a Nigerian community: a descriptive study. *Pharm Pract* 2017; 15: 873–873.
5. World Health Organization. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. Scientific brief. *Pediatr Med Rodzinna* 2020; 16(1): 118–119.
6. Garrote A and Bonet R. El papel de los AINE en el tratamiento analgésico. *OFFARM* 2003; 22(10): 56–62.
7. Hariforoosh S, Asghar W and Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. *J Pharm Sci* 2013; 16(5): 821–847.
8. Blozik E, Rapold R, von Overbeck J, et al. Polypharmacy and potentially inappropriate medication in the adult, community-dwelling population in Switzerland. *Drugs Aging* 2013; 30(7): 561–568.
9. Cuevas R, Samaniego L, Acosta P, et al. Self-medication profile of employees in a pharmaceutical industry. *Memorias del Inst Investig en Ciencias la Salud* 2019; 17(1): 99–112.
10. Pillaca Medina ML and Carrión Domínguez K. Automedicación en personas adultas que acuden a boticas del Distrito Jesús Nazareno, Ayacucho 2015. *An Fac Med* 2016; 77(4): 387.
11. Mendoza-Chuctaya G, Cubas-Llalle WS, Mejia CR, et al. The population's perceptions of generic drugs compared to original brand-name drugs in Peruvian hospitals. *Cad Saude Publica* 2019; 35(10): e00065118.
12. Socal MP, Bai G and Anderson GF. Factors associated with prescriptions for branded medications in the medicare part D program. *JAMA Network Open* 2021; 4(3): e210483.

13. Wineinger NE, Zhang Y and Topol EJ. Trends in prices of popular brand-name prescription drugs in the United States. *JAMA Network Open* 2019; 2(5): e194791–e194791.
14. Goldman DP, Joyce GF and Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. *JAMA* 2007; 298(1): 61–69.
15. Briesacher BA, Andrade SE, Fouayzi H, et al. Medication adherence and use of generic drug therapies. *Am J Manag Care* 2009; 15(7): 450–456.
16. Francis SA, Barnett N and Denham M. Switching of prescription drugs to over-the-counter status. Is it a good thing for the elderly? *Drugs Aging* 2005; 22(5): 361–370.
17. Arencibia ZB and Choonara I. Balancing the risks and benefits of the use of over-the-counter pain medications in children. *Drug Safety* 2012; 35: 1119–1125.
18. Escalante Arias CP. *Automedicación con antiinflamatorios no esteroideos en adultos mayores del centro del adulto mayor José Leonardo Ortiz durante enero-abril, 2021*. Universidad Católica Santo Toribio de Mogrovejo, <http://tesis.usat.edu.pe/handle/20.500.12423/5869> (2023).
19. Aminoshariae A, Kulild JC and Donaldson M. Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: an updated systematic review. *J Am Dent Assoc* 2016; 147(2): 98–110.
20. Faqih AHMA and Sayed SF. Self-medication practice with analgesics (NSAIDs and acetaminophen), and antibiotics among nursing undergraduates in University College Farasan Campus, Jazan University, KSA. *Ann Pharm Fr* 2021; 79(3): 275–285.
21. Rodríguez-Lago I, Mesonero F, Hijos-Mallada G, et al. ACCU, GETECCU, GETEII. Self-medication with analgesics reported by patients with ulcerative colitis: an anonymous survey. *Gastroenterol Hepatol* 2022; 45(6): 457–463.
22. Abdu N, Mosazghi A, Teweldemedhin S, et al. NonSteroidal Anti-Inflammatory Drugs (NSAIDs): usage and co-prescription with other potentially interacting drugs in elderly: a cross-sectional study. *PLoS One* 2020; 15(10): e0238868.
23. Hwang AY and Smith SM. U.S. trends in prescription non-steroidal anti-inflammatory drug use among patients with cardiovascular disease, 1988–2016. *Pharmacotherapy* 2021; 41(3): 247–256.
24. da Silva Dal Pizzol T, Turmina Fontanella A, Cardoso Ferreira MB, et al. Analgesic use among the Brazilian population: results from the national survey on access, use and promotion of rational use of medicines (PNAUM). *PLoS One* 2019; 14(2): e0214329.
25. Laurell AC and Giovanella L. Health policies and systems in Latin America. In: *Oxford research encyclopedia of global public health*. Oxford University Press, 2018.
26. Cetrángolo O, Bertranou F, Casanova L, et al. *EL SISTEMA DE SALUD DEL PERÚ: situación actual y estrategias para orientar la extensión de la cobertura contributiva*. Lima, http://www.ilo.org/global/docs/WCMS_213905/lang-es/index.htm (2013, accessed 6 January 2022).
27. Herrera-Añazco P, Mougenot B, Benites-Meza JK, et al. Self-medication practices, use of brand-name, and over-the-counter medicines by Peruvian older adults. *Can Geriatr J* 2023; 26(1): 187–199.
28. Instituto Nacional de Estadística e Informática. Encuesta Nacional de Satisfacción de Usuarios de Salud. *SUSALUD*, <http://portal.susalud.gob.pe/wp-content/uploads/archivo/encuesta-sat-nac/2015/INFORME-FINAL-SATISFACCION-2015.pdf> (2016).
29. Benites-Meza JK, Herrera-Añazco P, Santillán-Rodríguez AA, et al. Association between self-medication with antibiotics and purchase of brand-name drugs: analysis of a national survey in Peru. *J Pharm Health Serv Res* 2023; 14(2): 112–122.
30. Uyen-Cateriano A, Herrera-Añazco P, Mougenot B, et al. Nonmedical switching of prescription medications, brand-name drugs and out-of-pocket spending on medicines among Peruvian adults. *J Pharm Health Serv Res* 2021; 12(4): 492–501.
31. Sánchez Prado RE, Núñez Quezada TDC, Dután Torres FB, et al. Revisión Bibliográfica sobre Automedicación con Antiinflamatorios no Esteroideos en la Población. *Cienc Lat Rev Científica Multidiscip* 2024; 8(1): 359–377.
32. Mayma Aguirre C and Orellana torres G. *Influencia de la publicidad en la decisión de compra de productos farmacéuticos antiinflamatorios no esteroideos de venta libre (AINE) en consumidores de Lima Metropolitana durante el mes de Setiembre de 2012*. 2013.
33. Sico JJ, Seng EK, Wang K, et al. Characteristics and gender differences of headache in the veterans health administration a national cohort study, fiscal year 2008–2019. *Neurology* 2022; 99(18): E1993–E2005.
34. Mirdad OA, Esheba GE, Mousa AH, et al. Over-the-counter medication use among parents in Saudi Arabia. *Int J Environ Res Public Health* 2023; 20(2): 1193.
35. Tesfamariam S, Anand IS, Kaleab G, et al. Self-medication with over the counter drugs, prevalence of risky practice and its associated factors in pharmacy outlets of Asmara, Eritrea. *BMC Public Health* 2019; 19(1): 159.
36. Mezones-Holguín E, Amaya E, Bellido-Boza L, et al. Cobertura de aseguramiento en salud: el caso peruano desde la Ley de Aseguramiento Universal. *Revista peruana de medicina experimental y salud pública* 2019; 36(2): 196–206.
37. Montañez Ginocchio VA. *Análisis del gasto de bolsillo en salud en Perú*, <https://eprints.ucm.es/49480/1/T40330.pdf> (2018).
38. Ministerio de Salud. *Análisis de Situación de Salud del Perú 2019*, http://bvs.minsa.gob.pe/local/OGEI/62_MAPASALUD1993.pdf (2019).
39. Bussmann RW and Sharon D. Medicinal plants of the andes and the amazon - The magic and medicinal flora of Northern Peru. *Ethnobotany Res Appl* 2016; 16: 1–295.
40. Hernández-Vásquez A, Alarcon-Ruiz CA, Díaz-Seijas D, et al. Purchase of medications without prescription in Peru: A cross-sectional population-based study. *F1000Res* 2019; 7: 1392.
41. Mezones-Holguín E, Solis-Cóndor R, Benites-Zapata VA, et al. Diferencias institucionales en el insuficiente acceso efectivo a medicamentos prescritos en instituciones prestadoras de servicios de salud en Perú: Análisis de la Encuesta Nacional de Satisfacción de Usuarios de los Servicios de Salud (ENSUSALUD 2014). *Revista Peruana de Medicina Experimental y Salud Pública* 2016; 33(2): 205–214.

42. Ugarte Ubilluz O. Estrategias para mejorar el acceso a medicamentos en el Perú. *An Fac Med* 2019; 80(1): 104–108.
43. Sewell K, Andreae S, Luke E, et al. Perceptions of and barriers to use of generic medications in a rural African American population, Alabama, 2011. *Prev Chronic Dis* 2012; 9: E142.
44. Iosifescu A, Halm EA, McGinn T, et al. Beliefs about generic drugs among elderly adults in hospital-based primary care practices. *Patient Educ Couns* 2008; 73(2): 377–383.
45. Almeida Cerino MJ, Priego Álvarez HR, Córdova Hernández JA, et al. Automedicación de medicamentos genéricos en usuarios de farmacias en un municipio mexicano. *Revista de la Facultad de Ciencias de la Salud Universidad del Cauca* 2020; 22(1): 24–32.
46. Instituto Nacional de Estadística e Informática. Perú. Perfil sociodemográfico. Informe Nacional. Censos Nacionales 2017: XII de Población, VII de Vivienda y III de Comunidades Indígenas. *INEI*.
47. Cardile S, Martinelli M, Barabino A, et al. Italian survey on nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding in children. *World J Gastroenterol* 2016; 22(5): 1877–1883.
48. Schneider V, Lévesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. *Am J Epidemiol* 2006; 164(9): 881–889.
49. Straube S, Tramèr MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. *BMC Gastroenterol* 2009; 9(1): 7.
50. Phueanpinit P, Pongwecharak J, Sumanont S, et al. Physicians' communication of risks from nonsteroidal anti-inflammatory drugs and attitude towards providing adverse drug reaction information to patients. *J Eval Clin Pract* 2017; 23(6): 1387–1394.
51. Sessa M, Sportiello L, Mascolo A, et al. Campania preventability assessment committee (Italy): a focus on the preventability of nonsteroidal anti-inflammatory drugs' adverse drug reactions. *Front Pharmacol* 2017; 8: 305.
52. Mestre-Ferrandiz J. Reference prices and generic medicines: what can we expect? *J Generic Med* 2003; 1(1): 31–38.
53. Ministerio de Salud. Resolución Ministerial N° 302-2020-MINSA - Gobierno del Perú, <https://www.gob.pe/institucion/minsa/normas-legales/580725-302-2020-minsa> (2020, accessed 7 January 2022).